Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Factors associated with willingness to wear an electronic overdose detection device.

Ahamad K, Dong H, Johnson C, Hyashi K, DeBeck K, Milloy MJ, Wood E.

Addict Sci Clin Pract. 2019 Jul 3;14(1):23. doi: 10.1186/s13722-019-0153-5.

2.

Strategies to Identify Patient Risks of Prescription Opioid Addiction When Initiating Opioids for Pain: A Systematic Review.

Klimas J, Gorfinkel L, Fairbairn N, Amato L, Ahamad K, Nolan S, Simel DL, Wood E.

JAMA Netw Open. 2019 May 3;2(5):e193365. doi: 10.1001/jamanetworkopen.2019.3365.

3.

Successful Management of Gamma-hydroxybutyrate (GHB) Withdrawal Using Baclofen as a Standalone Therapy: A Case Report.

Habibian S, Ahamad K, McLean M, Socias ME.

J Addict Med. 2019 Sep/Oct;13(5):415-417. doi: 10.1097/ADM.0000000000000514.

PMID:
30907765
4.

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report.

Prinsloo G, Ahamad K, Socías ME.

Subst Abus. 2019 Mar 4:1-3. doi: 10.1080/08897077.2019.1576086. [Epub ahead of print]

PMID:
30829174
5.

In-hospital training in addiction medicine: A mixed-methods study of health care provider benefits and differences.

Gorfinkel L, Klimas J, Reel B, Dong H, Ahamad K, Fairgrieve C, McLean M, Mead A, Nolan S, Small W, Cullen W, Wood E, Fairbairn N.

Subst Abus. 2019;40(2):207-213. doi: 10.1080/08897077.2018.1561596. Epub 2019 Jan 28.

PMID:
30689528
6.

Safety of a Modified Community Trailer to Manage Patients with Presumed Fentanyl Overdose.

Scheuermeyer FX, Grafstein E, Buxton J, Ahamad K, Lysyshyn M, DeVlaming S, Prinsloo G, Van Veen C, Kestler A, Gustafson R.

J Urban Health. 2019 Feb;96(1):21-26. doi: 10.1007/s11524-018-0321-z.

PMID:
30324356
7.

Will This Hospitalized Patient Develop Severe Alcohol Withdrawal Syndrome?: The Rational Clinical Examination Systematic Review.

Wood E, Albarqouni L, Tkachuk S, Green CJ, Ahamad K, Nolan S, McLean M, Klimas J.

JAMA. 2018 Aug 28;320(8):825-833. doi: 10.1001/jama.2018.10574. Review. Erratum in: JAMA. 2019 Jul 23;322(4):369.

PMID:
30167704
8.

The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.

Socias ME, Ahamad K, Le Foll B, Lim R, Bruneau J, Fischer B, Wild TC, Wood E, Jutras-Aswad D.

Contemp Clin Trials. 2018 Jun;69:21-27. doi: 10.1016/j.cct.2018.04.001. Epub 2018 Apr 5.

9.

Management of opioid use disorders: a national clinical practice guideline.

Bruneau J, Ahamad K, Goyer MÈ, Poulin G, Selby P, Fischer B, Wild TC, Wood E; CIHR Canadian Research Initiative in Substance Misuse.

CMAJ. 2018 Mar 5;190(9):E247-E257. doi: 10.1503/cmaj.170958. No abstract available.

10.

Increasing diversion of methadone in Vancouver, Canada, 2005-2015.

Reddon H, Ho J, DeBeck K, Milloy MJ, Liu Y, Dong H, Ahamad K, Wood E, Kerr T, Hayashi K.

J Subst Abuse Treat. 2018 Feb;85:10-16. doi: 10.1016/j.jsat.2017.11.010. Epub 2017 Nov 28.

11.

Barriers and facilitators to implementing addiction medicine fellowships: a qualitative study with fellows, medical students, residents and preceptors.

Klimas J, Small W, Ahamad K, Cullen W, Mead A, Rieb L, Wood E, McNeil R.

Addict Sci Clin Pract. 2017 Sep 20;12(1):21. doi: 10.1186/s13722-017-0086-9.

12.

Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Panagiotoglou D, Krebs E, Min JE, Olding M, Ahamad K, Ti L, Montaner JSG, Nosyk B.

Int J Drug Policy. 2017 Sep;47:169-176. doi: 10.1016/j.drugpo.2017.05.021. Epub 2017 Jun 1.

13.

Impact of a brief addiction medicine training experience on knowledge self-assessment among medical learners.

Klimas J, Ahamad K, Fairgrieve C, McLean M, Mead A, Nolan S, Wood E.

Subst Abus. 2017 Apr-Jun;38(2):141-144. doi: 10.1080/08897077.2017.1296055. Epub 2017 Feb 21.

14.

Two birds with one stone: experiences of combining clinical and research training in addiction medicine.

Klimas J, McNeil R, Ahamad K, Mead A, Rieb L, Cullen W, Wood E, Small W.

BMC Med Educ. 2017 Jan 23;17(1):22. doi: 10.1186/s12909-017-0862-y.

15.

Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial.

Korthuis PT, Lum PJ, Vergara-Rodriguez P, Ahamad K, Wood E, Kunkel LE, Oden NL, Lindblad R, Sorensen JL, Arenas V, Ha D, Mandler RN, McCarty D; CTN-0055 CHOICES Investigators.

Addiction. 2017 Jun;112(6):1036-1044. doi: 10.1111/add.13753. Epub 2017 Feb 8.

16.

Low-Cost, Robust, and Field Portable Smartphone Platform Photometric Sensor for Fluoride Level Detection in Drinking Water.

Hussain I, Ahamad KU, Nath P.

Anal Chem. 2017 Jan 3;89(1):767-775. doi: 10.1021/acs.analchem.6b03424. Epub 2016 Dec 16.

PMID:
27982569
17.

An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders.

Socías ME, Ahamad K.

CMAJ. 2016 Dec 6;188(17-18):1208-1209. doi: 10.1503/cmaj.160554. Epub 2016 Nov 7. No abstract available.

18.

Treatment of opioid use disorder in an innovative community-based setting after multiple treatment attempts in a woman with untreated HIV.

Voon P, Joe R, Fairgrieve C, Ahamad K.

BMJ Case Rep. 2016 Jul 11;2016. pii: bcr2016215557. doi: 10.1136/bcr-2016-215557.

19.

The Impact of Benzodiazepine Use on Mortality Among Polysubstance Users in Vancouver, Canada.

Walton GR, Hayashi K, Bach P, Dong H, Kerr T, Ahamad K, Milloy MJ, Montaner J, Wood E.

Public Health Rep. 2016 May-Jun;131(3):491-9.

20.

A Needs Assessment of the Number of Comprehensive Addiction Care Physicians Required in a Canadian Setting.

McEachern J, Ahamad K, Nolan S, Mead A, Wood E, Klimas J.

J Addict Med. 2016 Jul-Aug;10(4):255-61. doi: 10.1097/ADM.0000000000000230.

21.

A delayed injection-site reaction in a patient receiving extended-release naltrexone.

Ahamad K, Korthuis PT, Lum PJ, Johnson C, Wood E.

Subst Abus. 2016 Apr-Jun;37(2):278-80. doi: 10.1080/08897077.2016.1138919.

22.

Increasing awareness about HIV prevention among young people who initiated injection drug use in a Canadian setting, 1988-2014.

Bahji A, Wood E, Ahamad K, Dong H, DeBeck K, Milloy MJ, Kerr T, Hayashi K.

Int J Drug Policy. 2015 Dec;26(12):1258-64. doi: 10.1016/j.drugpo.2015.09.010. Epub 2015 Sep 30.

23.

Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study.

Ahamad K, Hayashi K, Nguyen P, Dobrer S, Kerr T, Schütz CG, Montaner JS, Wood E.

Lancet HIV. 2015 Oct;2(10):e445-50. doi: 10.1016/S2352-3018(15)00129-0. Epub 2015 Aug 6. Erratum in: Lancet HIV. 2015 Nov;2(11):e463.

24.

Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest.

Walton G, Nolan S, Sutherland C, Ahamad K.

BMJ Case Rep. 2015 Sep 21;2015. pii: bcr2015210239. doi: 10.1136/bcr-2015-210239.

25.

The 'Expanded HIV care in opioid substitution treatment' (EHOST) cluster-randomized, stepped-wedge trial: A study protocol.

Nosyk B, Krebs E, Min JE, Ahamad K, Buxton J, Goldsmith C, Hull M, Joe R, Krajden M, Lima VD, Olding M, Wood E, Montaner JSG.

Contemp Clin Trials. 2015 Nov;45(Pt B):201-209. doi: 10.1016/j.cct.2015.08.020. Epub 2015 Sep 3.

PMID:
26342295
26.

Impact of binge alcohol on mortality among people who inject drugs.

Johnson C, Dong H, Ahamad K, Hayashi K, Milloy MJ, Kerr T, Wood E.

Addict Behav Rep. 2015 Dec 1;2:28-32.

27.

Pharmacotherapy for alcohol addiction in a patient with alcoholic cirrhosis and massive upper gastrointestinal bleed: A case study.

Young S, Wood E, Ahamad K.

Drug Alcohol Rev. 2016 Mar;35(2):236-9. doi: 10.1111/dar.12289. Epub 2015 Jun 18.

28.

Dose-response relationship between methadone dose and adherence to antiretroviral therapy among HIV-positive people who use illicit opioids.

Lappalainen L, Nolan S, Dobrer S, Puscas C, Montaner J, Ahamad K, Dong H, Kerr T, Wood E, Milloy MJ.

Addiction. 2015 Aug;110(8):1330-9. doi: 10.1111/add.12970.

29.

Factors associated with willingness to take extended release naltrexone among injection drug users.

Ahamad K, Milloy MJ, Nguyen P, Uhlmann S, Johnson C, Korthuis TP, Kerr T, Wood E.

Addict Sci Clin Pract. 2015 May 3;10:12. doi: 10.1186/s13722-015-0034-5.

30.

Factors associated with willingness to participate in a pharmacologic addiction treatment clinical trial among people who use drugs.

Uhlmann S, Milloy MJ, Ahamad K, Nguyen P, Kerr T, Wood E, Richardson L.

Am J Addict. 2015 Jun;24(4):368-73. doi: 10.1111/ajad.12200. Epub 2015 Mar 24.

31.

Gender influences on initiation of injecting drug use.

Ahamad K, Debeck K, Feng C, Sakakibara T, Kerr T, Wood E.

Am J Drug Alcohol Abuse. 2014 Mar;40(2):151-6. doi: 10.3109/00952990.2013.860983. Epub 2014 Jan 9.

32.
33.

Supplemental Content

Loading ...
Support Center